NUDCD3 Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-09934
Key Product Details
Species Reactivity
Human
Applications
Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Rabbit
Concentration
0.5 mg/ml
Product Specifications
Immunogen
The immunogen for Anti-NUDCD3 antibody is: synthetic peptide directed towards the middle region of Human NUDC3 (NP_056147.2). Peptide sequence AHGSQEAEAPGAVAGAAEVPREPPILPRIQEQFQKNPDSYNGAVRENYTW
Clonality
Polyclonal
Host
Rabbit
Theoretical MW
39 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Scientific Data Images for NUDCD3 Antibody
Western Blot: NUDCD3 Antibody [NBP3-09934]
Western Blot: NUDCD3 Antibody [NBP3-09934] - Western blot analysis of NUDCD3 in Human Fetal Liver. Antibody dilution at 1 ug/mLApplications for NUDCD3 Antibody
Application
Recommended Usage
Western Blot
1.0 ug/ml
Formulation, Preparation, and Storage
Purification
Affinity purified
Formulation
PBS, 2% Sucrose
Preservative
0.09% Sodium Azide
Concentration
0.5 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: NUDCD3
Alternate Names
KIAA1068NudCL, NudC domain containing 3, nudC domain-containing protein 3, NudC-like protein
Gene Symbol
NUDCD3
Additional NUDCD3 Products
Product Specific Notices for NUDCD3 Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...